Advisornet Financial’s Standard BioTools LAB Stock Holding History

Advisornet Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,500	Closed	-$39K	–	1787
2020 Q4	$39K	Buy	+6,500	New	+$42.7K	﹤0.01%	940

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Advisornet Financial's LAB Position: Q1 2021 in Review

Advisornet Financial sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 6,500 shares — an estimated $39K sold.

Advisornet Financial first reported a position in LAB in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

Advisornet Financial reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
Advisornet Financial sold 6,500 Standard BioTools shares in Q1 2021, an estimated $39K.
Advisornet Financial first reported a position in Standard BioTools in Q4 2020 and held it in 1 quarter.
Advisornet Financial's Standard BioTools position peaked at $39K in Q4 2020.
138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Advisornet Financial's 13F filing for Q1 2021, filed 14 Apr 2021.